Kenvue Inc. (NYSE:KVUE) Position Raised by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 10.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 36,956 shares of the company’s stock after buying an additional 3,399 shares during the period. Kestra Private Wealth Services LLC’s holdings in Kenvue were worth $796,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Empirical Finance LLC acquired a new stake in shares of Kenvue in the third quarter valued at $336,000. UniSuper Management Pty Ltd bought a new stake in Kenvue in the third quarter worth about $35,544,000. Citizens Business Bank acquired a new stake in Kenvue in the 3rd quarter valued at about $2,507,000. Fifth Third Bancorp boosted its position in shares of Kenvue by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock valued at $5,976,000 after purchasing an additional 72,435 shares in the last quarter. Finally, Clearbridge Investments LLC grew its stake in shares of Kenvue by 364.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock worth $9,725,000 after purchasing an additional 380,071 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on KVUE shares. The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. JPMorgan Chase & Co. reduced their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Sanford C. Bernstein assumed coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. Finally, Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $24.85.

Kenvue Stock Performance

NYSE:KVUE opened at $19.20 on Friday. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. The stock’s 50-day moving average is $19.82 and its two-hundred day moving average is $20.12.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue’s revenue was down 2.7% compared to the same quarter last year. Sell-side analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.17%. The ex-dividend date of this dividend is Tuesday, May 7th.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.